Evommune Inc (EVMN) is now in the Overvalued zone, suggesting that its current forward PS ratio of 327.40 is considered Overvalued compared with the five-year average of -5.83. The fair price of Evommune Inc (EVMN) is between 21.08 to 24.10 according to relative valuation method. Compared to the current price of 25.61 USD , Evommune Inc By Overvalued By 6.24%.

Relative Value

Fair Zone

21.08-24.10

Current Price：25.61

6.24%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Evommune Inc (EVMN) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Evommune Inc (EVMN) has a current Price-to-Book (P/B) ratio of -0.15. Compared to its 3-year average P/B ratio of -0.16, the current P/B ratio is approximately -7.66% higher. Relative to its 5-year average P/B ratio of -0.16, the current P/B ratio is about -7.66% higher. Evommune Inc (EVMN) has a Forward Free Cash Flow (FCF) yield of approximately -14.36%. Compared to its 3-year average FCF yield of -13.74%, the current FCF yield is approximately 4.58% lower. Relative to its 5-year average FCF yield of -13.74%, the current FCF yield is about 4.58% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for EVMN competitors is 59.06, providing a benchmark for relative valuation. Evommune Inc Corp (EVMN.N) exhibits a P/S ratio of 327.40, which is 454.35% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of EVMN increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of EVMN in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is EVMN currently overvalued or undervalued?

What is Evommune Inc (EVMN) fair value?

EVMN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Evommune Inc (EVMN) is between 21.08 to 24.10 according to relative valuation method.

How does EVMN's valuation metrics compare to the industry average?

The average P/S ratio for EVMN's competitors is 59.06, providing a benchmark for relative valuation. Evommune Inc Corp (EVMN) exhibits a P/S ratio of 327.40, which is 454.35% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Evommune Inc (EVMN) as of Mar 03 2026?

As of Mar 03 2026, Evommune Inc (EVMN) has a P/B ratio of -0.15. This indicates that the market values EVMN at -0.15 times its book value.

What is the current FCF Yield for Evommune Inc (EVMN) as of Mar 03 2026?

As of Mar 03 2026, Evommune Inc (EVMN) has a FCF Yield of -14.36%. This means that for every dollar of Evommune Inc's market capitalization, the company generates -14.36 cents in free cash flow.

What is the current Forward P/E ratio for Evommune Inc (EVMN) as of Mar 03 2026?

As of Mar 03 2026, Evommune Inc (EVMN) has a Forward P/E ratio of -5.38. This means the market is willing to pay $-5.38 for every dollar of Evommune Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Evommune Inc (EVMN) as of Mar 03 2026?

As of Mar 03 2026, Evommune Inc (EVMN) has a Forward P/S ratio of 327.40. This means the market is valuing EVMN at $327.40 for every dollar of expected revenue over the next 12 months.

EVMN Valuation